MRTP is a designation from the U.S. Food and Drug Administration (FDA) which means that the product may be marketed with reduced risk or reduced exposure information.
On July 7, 2020, the FDA authorized IQOS to be marketed in the U.S. with reduced exposure information.
The FDA came to this decision after several years of reviewing the scientific evidence provided by Philip Morris International.